After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

19日の米株式市場で米バイオテクノロジー企業ノババックスの株価が急伸した。米規制当局が同社の新型コロナウイルスワクチンを完全に承認したことで、承認遅延や有効性を疑問視するケネディ厚生長官の発言により高まっていた市場の不安が和らいだ。

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.